Management of diabetic nephropathy: the role of sirtuin-1

References

• 1. Hong Q, Zhang L, Das B et al. Increased podocyte Sirtuin-1 function attenuates diabetic kidney injury. Kidney Int. 93(6), 1330–1343 (2018).
  Medline CASGoogle Scholar
• 2. Kitada M, Takeda A, Nagai T, Ito H, Kanasaki K, Koya D. Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of SIR1 in diabetic Wistar fatty (fa/fa) rats: a model of Type 2 diabetes. Exp. Diabetes Res. 2011, 1–11 (2011).
  Google Scholar
• 3. Mansur AP, Roggerio A, Goes MFS et al. Serum concentrations and gene expression of sirtuin 1 in healthy and slightly overweight subjects after caloric restriction or resveratrol supplementation: a randomized trial. Int. J. Cardiol. 227, 788–794 (2017).
  MedlineGoogle Scholar
• 4. Liu HW, Kao HH, Wu CH. Exercise training upregulates SIRT1 to attenuate inflammation and metabolic dysfunction in kidney and liver of diabetic db/db mice. Nutr. Metab. (Lond.) 16, 22 (2019).
  MedlineGoogle Scholar
• 5. Tang LX, Wang B, Wu ZK. Aerobic exercise training alleviates renal injury by interfering with mitochondrial function in Type-1 diabetic mice. Med. Sci. Monit. 24, 9081–9089 (2018).
  Medline CASGoogle Scholar
• 6. Rogacka D, Audzeyenka I, Rychlowski M et al. Metformin overcomes high glucose-induced insulin resistance of podocytes by pleiotropic effects on SIRT1 and AMPK. Biochim. Biophys. Acta 1864(1), 115–125 (2018).
  CASGoogle Scholar
• 7. Zhai L, Gu J, Yang D, Hu W, Wang W, Ye S. Metformin ameliorates podocyte damage by restoring renal tissue nephrin expression in Type 2 diabetic rats. J. Diabetes 9(5), 510–517 (2017).
  Medline CASGoogle Scholar
• 8. Wang C, Li L, Liu S et al. GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis. PLoS ONE 13(3), e0193473, 1–16 (2018).
  MedlineGoogle Scholar
• 9. Wanner C, Inzucchi SE, Lachin JM et al. Empagliflozin and progression of kidney disease in Type 2 diabetes. N. Engl. J. Med. 375(4), 323–334 (2016).
  Medline CASGoogle Scholar
• 10. Kim H, Baek CH, Lee RB, Chang JW, Yang WS, Lee SK. Anti-fibrotic effect of losartan, an angiotensin II receptor blocker, is mediated through inhibition of ER stress via up-regulation of SIRT1, followed by induction of HO-1 and thioredoxin. Int. J. Mol. Sci. 18(2), pii:E305 (2017).
  Google Scholar
• 11. Gu J, Yang M, Qi N et al. Olmesartan prevents microalbuminuria in db/db diabetic mice through inhibition of angiotensin II/p38/SIRT1-induced podocyte apoptosis. Kidney Blood Press. Res. 41(6), 848–864 (2016).
  Medline CASGoogle Scholar
• 12. Mendez-Del Villar M, Gonzalez-Ortiz M, Martinez-Abundis E, Perez-Rubio KG, Lizarraga-Valdez R. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab. Syndr. Relat. Disord. 12(10), 497–501 (2014).
  MedlineGoogle Scholar
• 13. Sattarinezhad A, Roozbeh J, Shirazi Yeganeh B, Omrani GR, Shams M. Resveratrol reduces albuminuria in diabetic nephropathy: a randomized double-blind placebo-controlled clinical trial. Diabetes Metab. 45(1), 53–59 (2019).
  Medline CASGoogle Scholar
• 14. Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS. Resveratrol-associated renal toxicity. Toxicol. Sci. 82(2), 614–619 (2004).
  Medline CASGoogle Scholar
• 15. Xu X, Zheng N, Chen Z, Huang W, Liang T, Kuang H. Puerarin, isolated from Pueraria lobata (Willd.), protects against diabetic nephropathy by attenuating oxidative stress. Gene 591(2), 411–416 (2016).
  Medline CASGoogle Scholar
• 16. Wang B, Chen S, Yan X et al. The therapeutic effect and possible harm of puerarin for treatment of stage III diabetic nephropathy: a meta-analysis. Altern. Ther. Health Med. 21(1), 36–44 (2015).
  MedlineGoogle Scholar
• 17. Oza MJ, Kulkarni YA. Formononetin attenuates kidney damage in Type 2 diabetic rats. Life Sci. 219, 109–121 (2019).
  Medline CASGoogle Scholar
• 18. Wang X, Gao Y, Tian N et al. Astragaloside IV inhibits glucose-induced epithelial-mesenchymal transition of podocytes through autophagy enhancement via the SIRT-NF-kappaB p65 axis. Sci. Rep. 9(1), 323 (2019).
  MedlineGoogle Scholar
• 19. Milne JC, Lambert PD, Schenk S et al. Small molecule activators of SIRT1 as therapeutics for the treatment of Type 2 diabetes. Nature 450(7170), 712–716 (2007).
  Medline CASGoogle Scholar
• 20. Pacholec M, Bleasdale JE, Chrunyk B et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem. 285(11), 8340–8351 (2010).
  Medline CASGoogle Scholar